Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 ,inter alia, to consider and approve 1. To consider and approve Un-audited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genpharmasec Limited has informed BSE that its Board of Directors will meet on Thursday, August 7, 2025, at the registered office in Mumbai. The main agenda is to consider and approve the Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 (Q1 FY26), along with the Limited Review Report. The intimation was filed under Regulation 29 of SEBI (LODR) Regulations, 2015. As per insider trading norms, the trading window has been closed from July 1, 2025 until 48 hours after the results are declared. The communication was signed by Mr. Sohan Chaturvedi, Whole Time Director & CFO.
No direct impact on the stock from this filing alone — it is a routine pre-results intimation. Investors should watch for the actual Q1 FY26 numbers on August 7, 2025, as those will drive any meaningful price movement. The closed trading window signals that insiders are barred from trading until results are out.